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Abstract
Background: Women in many countries are advised to use folic acid supplements before and early during
pregnancy to reduce the risk of neural tube defects in their infants. This study aimed to update the prevalence and
to identify possible determinants of preconception folic acid supplement use in Italian women.
Methods: The study was based on cross-sectional data from seven maternity clinics located in six Italian regions
from January to June, 2012. Data on maternal characteristics and supplement use were collected for 2,189 women
using a self-administered questionnaire.
Results: Preconception folic acid use was reported by 23.5 % (n = 515) of the participants. Of these, 479 (93 %)
women had taken folic acid supplements on a daily basis as recommended by the health authorities. Women who
both had intended their pregnancy and had requested a preconception health visit to a doctor/gynecologist were
substantially more likely than the reference group to initiate folic acid supplementation before their pregnancy (48.6
versus 4.8 %). Preconception folic acid use was also associated with higher maternal age, higher education,
marriage/cohabitation, lower parity, infertility treatments, and chronic disease.
Conclusions: Data from seven maternity clinics located in six Italian regions indicate that preconception folic acid
supplement use in many Italian women is low. Women who do not plan their pregnancy or do not request a
preconception health visit to their doctor have among the lowest prevalence of preconception folic acid use.
Improving folate status in these and other supplemental non-users may have important disease preventive effects.
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Background
Health authorities in many countries around the World
recommend women of reproductive age to use folic acid
supplements before and early in pregnancy to reduce the
risk of having a baby with a neural tube defect [1–3].
The recommendations usually indicate a dose of 0.4 mg
folic acid daily from at least one month before preg-
nancy until the third month of gestation. In addition to
such recommendations, a number of countries have also
introduced mandatory food fortification of grains with
folic acid to increase intake of this B-vitamin in fertile
women. In these countries, a risk reduction of neural
tube defect has been reported [4–7].
Mandatory food fortification with folic acid has not
yet been introduced in any European country [3, 8].
Enhanced sources of folate are only available from
folic acid supplements, voluntary fortification, and in-
take of foods rich in folates, such as vegetables and
fruits. Although the prevalence of preconception folic
acid supplementation in Europe has increased after
many years of delivered recommendations, a large
portion of women still does not follow the recom-
mendations and many start supplementation to late
with respect to neural tube defect prevention [9].
Additionally, the total prevalence of neural tube
defects in Europe has not declined markedly over the
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years [3, 10, 11]. This has led to a debate regarding the ef-
ficiency of folic acid recommendations in Europe and
other countries [12, 13].
In order to identify groups of women who do not fol-
low the recommendations, many researchers have ex-
plored the possible determinants of use or non-use of
folic acid supplements. Typically, pregnancy intention,
preconception health visit to a doctor, and higher educa-
tional level are strong correlates for taking folic acid
supplements [14–18], while higher parity, shorter and
longer interpregnancy intervals, maternal smoking be-
fore pregnancy, and lower maternal age are often associ-
ated with less use [15–19]. Such information is valuable
and can be used to design intervention programs to im-
prove the preconception folic acid supplement use over-
all and in subgroups of women related to low use.
In Italy, the official recommendations from April 2004
state that all women planning a pregnancy and those
who do not actively exclude the possibility of becoming
pregnant should take a daily folic acid supplement of at
least 0.4 mg from one month before conception and
continue throughout the first trimester [20, 21]. With a
prescription from a doctor, this dose or higher is free of
charge in Italy since 2005 [22]. Since the folic acid rec-
ommendations were issued in 2004, information on the
determinants of supplement use in Italian women is lim-
ited [14, 23, 24]. This study, therefore, aimed to update
the Italian prevalence and to identify possible determi-
nants of preconception folic acid supplement use in Ital-
ian women using data from a recent Italian multicenter
survey on preconception health.
Methods
Study population
The current study drew on resources of a multicenter study
initially established to examine the prevalence and the de-
terminants of a variety of preconception risk factors (in-
cluding preconception folic acid supplement use) in Italian
women [25]. It was conducted between January and June,
2012, in seven maternity clinics located in six different re-
gions: Castelli Hospital (Verbania, Piemonte), Vaio Hospital
(Fidenza, Emilia-Romagna), Galliera Hospital (Genova,
Liguria), Santa Chiara Hospital (Pisa, Toscana), S. Giovanni
Calibita Fatebenefratelli Hospital, and Santo Spirito Hos-
pital (Roma, Lazio), Rummo Hospital (Benevento, Campa-
nia). The study was approved by the ethical committee of
the S. Giovanni Calibita Fatebenefratelli Hospital (parere
55/2011).
The data collection of the present study has been de-
scribed elsewhere [25]. All women eligible for the study
were invited to fill in a self-administered questionnaire
comprising 35 initial questions on various topics, includ-
ing vitamin supplement use, pregnancy-related risk fac-
tors, and maternal background characteristics. Personal
information such as names, address, or birth date was not
recorded. In Verbania (n = 320), women were recruited
during pregnancy (usually at their first prenatal visits),
while in the other six maternity clinics (n = 1,892) mothers
were recruited during hospitalization after giving birth
[25]. Mothers of newborns with any congenital malforma-
tion or low birth weight (<2,500 g), with children who
were delivered preterm (<37 weeks gestation), or mothers
with children admitted to the neonatal intensive care unit
were initially not invited to participate to avoid subjecting
them to unnecessary stress. Also, women not speaking
Italian were excluded from the study.
The distribution of the 2,212 participants at the seven
participating maternity clinics was as follows: Verbania
(14.5 %), Genova (17.8 %), Fidenza (9.9 %), Pisa (9.1 %),
Roma Fatebenefratelli (23.1 %), Roma Santo Spirito
(10.8 %), and Benevento (14.7 %) [25]. Of the 2,212 par-
ticipating women, we excluded 23 women who did not
have information of folic acid supplement use (n = 5) or
did not provide information on the time period of use
(n = 18), leaving back 2,189 women for analyzes.
Folic acid supplement use
The women were asked to report data on supplemental
use of folic acid and other vitamins by specifying the
brand name, the frequency of use, as well as the time
period of use. In this study, we defined folic acid supple-
ment use as any use of supplements containing folic acid
for at least once a week during the following predefined
time periods: (a) at least one month before the last men-
strual period to the end of the first trimester, (b) at least
six months before the last menstrual period to the end
of the first trimester, (c) soon after pregnancy confirm-
ation to the end of the first trimester, (d) after the first
trimester of pregnancy, or (e) no use at all. The main
outcome variable under study was preconception folic
acid supplement use, i.e., any use of folic acid supple-
ments that had started before the last menstrual period
(category (a) and (b) above). Note that our definition of
preconception folic acid use differs somewhat from the
official recommendations by allowing for a more moder-
ate use as well, i.e., less than seven days a week.
Potential determinants
Based on the questionnaire, we abstracted data on the
following relevant determinants of folic acid supplement
use: maternal age at study recruitment (Verbania) or de-
livery (other regions), parity, maternal education, marital
status, national citizenship, working activity, pregnancy
intention, preconception health visit, infertility treat-
ment, maternal smoking, prepregnancy body mass index
(kg/m2), and chronic diseases. The pregnancy was classi-
fied as intended, mistimed or unintended on the basis of
a score of the intensity of pregnancy planning effort
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developed by Morin et al. [26] The following categories
were used: intended (score 9–12), mistimed (score 4–8)
and unintended (score: 0–3). The preconception health
visit was defined as any visit to a doctor/gynecologist
within the last year before the onset of pregnancy to ask
for any advice on the possible near future pregnancy,
such as medical examinations to perform, medications
and vitamins to take. Body mass index before pregnancy
was categorized into four groups according to the cri-
teria by the World Health Organization: underweight
(<18.50 kg/m2), normal weight (18.50–24.99 kg/m2),
pre-obese (25.00–29.99 kg/m2), obese (≥30.00 kg/m2).
Parity was defined as the number of previous live births
and stillbirths while maternal smoking was defined as
any smoking around the time of the last menstrual
period. Chronic diseases included diabetes, epilepsy,
asthma, and hypertension.
Statistical analysis
Statistical analyzes were performed by using SAS (Statis-
tical Analysis System) version 9.2 (SAS Institute, Inc.,
Cary, North Carolina) for Windows. Data were described
as percentages or means with interquartile ranges
(IQRs). The chi-square test was used to test for group
difference in categorical variables. All P values were two-
sided and values <0.05 were considered statistically sig-
nificant. Associations of preconception folic acid use
with the various maternal characteristics were estimated
by prevalence ratios with 95 % confidence intervals (CIs)
using log-binomial regression models with the log-link
function. All prevalence ratios were estimated by crude
models, as well as after adjustment for maternal age,
parity, maternal education, marital status, national citi-
zenship (here: Italian), pregnancy intention, preconcep-
tion health visit, infertility treatment, and maternal
smoking before pregnancy. All covariates have previ-
ously been strongly related to maternal folic acid supple-
ment use. Additionally, the correlation between binary
outcomes within the same maternity clinic was taken
into account by using generalized estimating equations
methodology, assuming an exchangeable working correl-
ation structure. Women with missing data on covariates
were excluded in multiple regression analyzes.
Results
Of the 2,189 participating women, the mean maternal
age was 33 (IQR: 29–37; range 13–50) years; only 6 %
were younger than 25 years while 40 % were older than
35 years (Table 1). We further estimated that 64 % of
the women had intended their pregnancy and that 30 %
had mistimed their pregnancy. Overall, 41 % of the
women reported that they had requested a preconcep-
tion health visit to a doctor/gynecologist whereas 7 %
had reported that they had used an infertility treatment.
Table 1 Characteristics of the study sample
Characteristic No. of womena
n %
Maternal age (years)
<25 130 5.9
25–29 404 18.5
30–34 724 33.1
35–39 660 30.2
40 or more 209 9.5
Parity
0 1,246 56.9
1 730 33.3
2 171 7.8
3 or more 42 1.9
Educational level
Primary school 331 15.1
Secondary school 960 43.9
University 890 40.7
Marital status
No partner 213 9.7
Married/cohabiting 1,957 89.4
Citizenship
Non-Italian 319 14.6
Italian 1,867 85.3
Working activity
Studying 106 4.8
Working 1,683 76.9
Working at home 283 12.9
Not working 94 4.3
Pregnancy intention
Unintended 121 5.5
Mistimed 646 29.5
Intended 1,392 63.6
Preconception health visit
No 1,266 57.8
Yes 907 41.4
Infertility treatment
No 2,001 91.4
Ovulation inductor use, no ART 31 1.4
ART 128 5.8
Maternal smoking before pregnancy
No 1,614 73.7
Yes 575 26.3
BMI before pregnancy
Underweight 180 8.2
Normal weight 1,573 71.9
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Reported smoking prevalence before the onset of preg-
nancy was as high as 26 %.
Overall, 84 % (n = 1,838) of the participating women
had taken folic acid supplements at some time point be-
fore and/or during pregnancy while only 23.5 % (n = 515)
of the participants had reported the use of folic acid sup-
plements before the onset of pregnancy. Specifically,
11.7 % (n = 256) of all women had initiated use, at least,
one month before pregnancy, 11.8 % (n = 259) had
initiated use, at least, six months before pregnancy, 54.9 %
(n = 1201) had initiated after pregnancy confirmation
during the first trimester, and 5.6 % (n = 122) reported
starting folic acid use after the first trimester of pregnancy
(Fig. 1).
For all subgroups of women, intake of folic acid use
was low during the preconception period and highest
after pregnancy confirmation (Table 2). In particular, the
initiation of supplement use in women younger than
25 years of age was only 5.4 % before pregnancy and
63 % soon after pregnancy confirmation.
Preconception folic acid use was reported by 23.5 %
(n = 515) of the participants. Of these, 479 (93 %) women
had taken folic acid supplements on a daily basis as rec-
ommended by the health authorities, 25 (4.9 %) women
had taken the supplements 4–6 times a week while 6
(1.2 %) women had taken them 1–3 times a week. Five
women (0.9%) did not report the frequency of use.
Unadjusted and adjusted regression analyses showed
that age over 25 years, being pregnant for the first time,
having a university degree/secondary school, being mar-
ried/cohabiting, intending the pregnancy, requesting
preconception health visit to a doctor/gynecologist,
using infertility treatments, and having chronic diseases
were all statistically significant determinants of precon-
ception folic acid use (Table 3). Italian citizenship, ovula-
tion inductor use, and non-smoking before pregnancy
were not significant determinants after adjustment for
covariates. Working status and body mass index before
pregnancy were insignificant determinants both before
and after covariate adjustments (Table 3).
Of the 515 women who had initiated use of folic acid-
containing supplements before the onset of pregnancy,
we had exact folic acid dose information on 506 women
(98.2 %). Of these, 71.5 % had taken the usual dose of
0.4 mg, 20.9 % had taken 0.4 mg to 5.0 mg while 7.5 %
had taken more than 5.0 mg (Fig. 2).
One-third of the women (n = 712) reported that they
had both intended their pregnancy and had requested a
preconception health visit to a doctor/gynecologist
(Table 4). These women were eight times more likely to
start folic acid supplementation before pregnancy com-
pared with those who did not intend and did not request
a preconception health visit (48.6 versus 4.8 %; adjusted
prevalence ratio = 7.90 [95 % CI: 4.62, 13.5]).
Table 1 Characteristics of the study sample (Continued)
Pre-obese 303 13.8
Obese 122 5.6
Chronic disease
No 1,959 89.5
Yes 208 9.5
Abbreviation: ART assisted reproductive technology, BMI body mass index
aPercentages do not add to 2,189 and 100 % due to missing data: 62 women
on maternal age, 8 women on educational level, 19 women on marital status,
3 women on citizenship, 23 women on working activity, 30 women on
pregnancy intention, 16 women on preconception health visit, 29 women on
infertility treatment, 11 women on body mass index before pregnancy, and 22
women with chronic disease
Fig. 1 The prevalence of folic acid supplement users according to time periods of use (n = 2,189). Time periods of use were defined as at least one
month before the last menstrual period to the end of the first trimester, at least six months before the last menstrual period to the end of the first
trimester, soon after pregnancy confirmation to the end of the first trimester, after the first trimester of pregnancy, or no use at all
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Table 2 Prevalence of folic acid supplement users according to maternal characteristics and time periods of usea
Characteristic No. of
women
Folic acid supplement users, %b
At least one month
before pregnancy
(n = 256)
At least six months
before pregnancy
(n = 259)
Soon after pregnancy
confirmation (n = 1,201)
After the first
trimester (n = 122)
Maternal age (years)
<25 130 5.4 0 63.1 7.7
25–29 404 11.4 7.4 58.7 4.7
30–34 724 13.5 10.9 54.4 6.2
35–39 660 12.3 15.8 51.1 5.2
40 or more 209 10.5 19.1 53.1 4.8
Parity
0 1,246 12.4 14.4 52.8 4.5
1 730 11.6 8.6 58.8 6.4
2 171 8.2 8.8 55.0 9.4
3 or more 42 4.8 2.4 47.6 7.1
Educational level
Primary school 331 3.9 5.4 53.5 8.2
Secondary school 960 11.3 10.2 56.3 6.9
University 890 15.1 16.1 54.2 3.3
Marital status
No partner 213 5.6 6.6 62.9 7.5
Married/cohabiting 1,957 12.3 12.5 54.2 5.4
Citizenship
Non-Italian 319 8.2 6.0 53.0 10.0
Italian 1,867 12.3 12.9 55.2 4.8
Working activity
Studying 106 10.4 7.5 61.3 5.7
Working 1,683 12.4 12.7 55.0 5.4
Working at home 283 8.5 8.8 53.7 6.0
Not working 94 10.6 13.8 50.0 7.4
Pregnancy intention
Unintended 121 4.1 2.5 57.0 9.1
Mistimed 646 4.3 4.0 62.4 7.3
Intended 1,392 15.8 16.4 51.1 4.4
Preconception health visit
No 1,266 5.1 5.0 63.6 6.8
Yes 907 21.2 21.6 42.9 3.9
Infertility treatment
No 2,001 11.0 9.9 57.0 5.5
Ovulation inductor use, no ART 31 6.5 41.9 32.3 12.9
ART 128 22.7 35.2 30.5 2.3
Maternal smoking before pregnancy
No 1,614 12.5 13.1 53.5 5.4
Yes 575 9.4 8.3 58.6 6.1
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Of 188 pregnancies that were not planned but in
which the mother had consulted a doctor/gynecologists
on preconception health advice (Table 4), 92 % (173/
188) were classified as mistimed. The prevalence of folic
acid supplement use in these 173 mistimed pregnancies
was 21.4 % (not shown).
Finally, the estimated prevalence of preconception
folic acid supplement use in the specific group of re-
sourceful women (those who aged over 25 years, had a
university degree, were married/cohabiting, had Italian
citizenship, intended their pregnancy, requested a pre-
conception visit) was 58.0 % [95 % CI: 52 %, 64 %],
which was twice as high as the preconception prevalence
of 23.5 % estimated for the total population.
Discussion
Our study showed that 84 % of women had taken folic
acid supplements at some time point before and/or dur-
ing the pregnancy but that only 23.5 % of the partici-
pants had initiated use before the onset of pregnancy. In
general, the percentage of initiation of folic acid supple-
ment use was low before the onset of pregnancy and
highest soon after pregnancy confirmation. This pattern
was seen in all subgroups of women and suggests that
the majority of women acquire folic acid information
firstly after the onset of pregnancy. The most important
determinants of folic acid use before the onset of preg-
nancy were preconception health visit to a doctor and
pregnancy intention.
This is among the largest studies to examine the
prevalence and determinants of maternal preconception
folic acid supplement use in Italy. Strengths of the study
include the detailed data on frequency, dose, and timing
of folic acid supplement use, the analysis of a large num-
ber of maternal characteristics as determinants of sup-
plement use, and the multicenter design in which data
were collected through seven maternity clinics from six
regions in Italy (three in the north, three in the center,
and one in the south). However, our study sample may
not be representative of all women giving birth in Italy.
Women who did not comprehend the Italian language,
those who delivered before 37 weeks of gestation or had
an infant with birth weight below 2,500 g were not in-
vited to participate. In addition, mothers with the lowest
educational level may have been underrepresented in
our study [27]. As these factors have been related to low
use, our study might have overestimated the prevalence
of preconception folic acid supplement use. Our preva-
lence estimate is still close to that reported in a previous
study, which was 25.4 % in Italians [23].
Our findings on determinants of preconception folic
acid use are generally consistent with those found in nu-
merous other studies. Higher maternal age, having
higher education, being married/cohabiting, having
lower parity, using infertility treatments, and having a
chronic disease have all been identified as statistically
significant determinants of preconception folic acid use
in previous studies [15–19]. In contrast to some find-
ings, we did not identify national citizenship [17] and
maternal smoking before pregnancy [15, 16] as signifi-
cant independent factors after adjusting for covariates.
Also, the association of ovulation inductor use was sub-
stantially attenuated after covariate adjustments, particu-
larly after adjustment of preconception health visit and
pregnancy intention (not shown). Consistent with two
other large studies [15, 16], prepregnancy body mass
index was not important determinants of preconception
folic acid use in our study, neither was working status.
We identified preconception health visit to a doctor/
gynecologist and pregnancy intention as the most import-
ant determinants of preconception folic acid supplement
use. Obviously, women who intend their pregnancy or seek
preconception advice from their doctor before pregnancy
may be more informed on the benefits and timing of folic
acid. Still, only 48.6 % (346/712) of all those who had re-
quested preconception health visit and also had intended
their pregnancy were using folic acid before pregnancy (see
Table 4). An explanation for the low proportion of
Table 2 Prevalence of folic acid supplement users according to maternal characteristics and time periods of usea (Continued)
BMI before pregnancy
Underweight 180 11.1 12.2 53.9 6.1
Normal weight 1,573 12.4 12.3 54.2 5.6
Pre-obese 303 11.2 9.9 59.4 4.3
Obese 122 5.7 9.8 54.9 6.6
Chronic disease
No 1,959 11.2 11.0 55.4 5.8
Yes 208 14.4 19.7 50.0 3.8
Abbreviation: ART assisted reproductive technology, BMI body mass index
aTime periods were defined as (a) at least one month before the last menstrual period to the end of the first trimester, (b) at least six months before the last
menstrual period to the end of the first trimester, (c) soon after pregnancy confirmation to the end of the first trimester, (d) after the first trimester of pregnancy,
or (e) no use at all
bPercentage of “no use at all” not shown in the table
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Table 3 Prevalence and association of preconception folic acid supplement according to reported maternal characteristics
Characteristic No. of
women
No. of
supplement
usersa
Crudeb Adjustedc
Prevalence ratio 95 % confidence interval Prevalence ratio 95 % confidence interval
N n %
Maternal age (years)
<25d 130 7 5.4 0.23 0.07, 0.80 0.31 0.12, 0.80
25–29 404 76 18.8 0.78 0.60, 1.01 0.94 0.79, 1.11
30–34 724 177 24.4 1 1
35–39 660 185 28.0 1.13 1.03, 1.23 1.05 0.96, 1.15
40 or more 209 62 29.7 1.18 1.03, 1.36 0.98 0.85, 1.14
Parity
0d 1,246 335 26.9 1 1
1 730 148 20.3 0.74 0.63, 0.86 0.86 0.77, 0.95
2 171 29 17.0 0.65 0.56, 0.76 0.82 0.57, 1.18
3 or more 42 3 7.1 0.24 0.08, 0.72 0.66 0.29, 1.51
Educational level
Primary schoold 331 31 9.4 1 1
Secondary school 960 206 21.5 1.99 1.73, 2.29 1.69 1.46, 1.95
University 890 277 31.1 2.80 2.41, 3.26 1.90 1.62, 2.22
Marital status
No partnerd 213 26 12.2 1 1
Married/cohabiting 1,957 485 24.8 2.26 1.86, 2.75 1.44 1.21, 1.72
Citizenship
Non-Italiand 319 45 14.1 1
Italian 1,867 470 25.2 2.32 1.21, 4.42 1.40 0.99, 1.97
Working activity
Studyingd 106 19 17.9 1 1
Working 1,683 422 25.1 1.47 0.89, 2.42 1.00 0.73, 1.36
Working at home 283 49 17.3 1.15 0.68, 1.96 1.10 0.77, 1.58
Not working 94 23 24.5 1.49 0.73, 3.06 1.31 0.88, 1.97
Pregnancy intention
Unintendedd 121 8 6.6 1 1
Mistimed 646 54 8.4 1.34 0.79, 2.28 1.02 0.61, 1.70
Intended 1,392 448 32.2 4.87 2.51, 9.43 2.40 1.14, 5.05
Preconception health visit
Nod 1,266 127 10.0 1 1
Yes 907 388 42.8 4.21 3.09, 5.72 2.90 2.21, 3.82
Infertility treatment
Nod 2,001 418 20.9 1 1
Ovulation inductor use, no ART 31 15 48.4 2.11 1.35, 3.29 1.00 0.62, 1.60
ART 128 74 57.8 2.75 2.08, 3.64 1.35 1.08, 1.68
Maternal smoking before pregnancy
Nod 1,614 413 25.6 1 1
Yes 575 102 17.7 0.70 0.59, 0.82 0.92 0.79, 1.07
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preconception folic acid users in this highly motivated
group may be that recommendations on folic acid supple-
ment use were not sufficiently provided to women by their
doctors or that, in spite of sufficient information, women
forgot or choose not to follow the doctor’s advice. These
and other specific reasons for not taking folic acid supple-
ments despite pregnancy planning and preconception
health visits should be further investigated in studies to
gain new insight on how to improve supplement use in
these women [14].
As many as 27 % (584/2,189) women did not intend their
pregnancy and did not request a preconception health visit
(see Table 4). Of these, only 5 % (28/584) used folic acid-
containing supplements before the onset of pregnancy.
Clearly, information on the benefits of folic acid had not
reached out to this large group of women, questioning the
efficiency of the official recommendations to fertile women.
To improve folate status in fertile women and particularly
in women with unintended pregnancies, many countries,
including the United States and Canada, have decided to
fortify their foods with folic acid. In these countries, a risk
reduction of neural tube defects has been reported [4–7].
Many countries refrain mandatory folic acid fortification,
partly because of the risk of masking anemia related to a
B12 deficiency in the elderly and partly because of un-
known cancer risks in the non-pregnant population [9].
Recent results, however, show that folic acid in fortified
foods and supplements does not interfere with vitamin B12
metabolism at the cellular level in a healthy population
[28]. Additionally, a recent meta-analysis showed no sig-
nificant risk (reduced or increased) of overall or site-
specific cancers in nearly 50,000 individuals from 13 differ-
ent randomized clinical trials of folic acid supplement use
[29]. Given that Italy does not fortify food with folic acid
and as many as 36 % mothers do not plan their pregnancy
[25], new effective strategies for increasing supplement use
in these pregnancies are strongly needed.
Of 188 pregnancies that were not planned but in
which the mother had consulted a doctor/gynecologists
on preconception health advice (see Table 4), 92 % (173/
188) were classified as mistimed. This suggests that
many women seeking preconception health advice had
not necessarily decided to become pregnant at the time
of the visit, but were open to the possibility of becoming
pregnant in the near future. The prevalence of folic acid
supplement use in these women was only 21.4 % and
might be substantially improved by more direct mea-
sures by their doctors.
Folates occur naturally in foods, predominantly in
green leafy vegetables, fruits, and cereal products.
Table 3 Prevalence and association of preconception folic acid supplement according to reported maternal characteristics
(Continued)
BMI before pregnancy
Underweightd 180 42 23.3 1 1
Normal weight 1,573 389 24.7 1.11 0.89, 1.38 0.97 0.75, 1.25
Pre-obese 303 64 21.1 1.01 0.81, 1.27 0.97 0.75, 1.26
Obese 122 19 15.6 0.77 0.53, 1.11 0.84 0.54, 1.31
Chronic disease
Nod 1,959 436 22.3 1 1
Yes 208 71 34.1 1.47 1.17, 1.85 1.22 1.09, 1.37
Abbreviation: ART assisted reproductive technology, BMI body mass index
aAny supplement use that started before the last menstrual period
bCrude prevalence ratio was estimated by log-binomial regression models
cAdjusted for maternal age, parity, maternal education, marital status, Italian citizenship, pregnancy intention, preconception health visit, infertility treatment, and
maternal smoking before pregnancy
dReference category
Fig. 2 The distribution of reported folic acid dose (mg) among
preconception supplement users (n = 515). Preconception folic acid
supplement use was defined as any use of folic acid supplements
that had started before the last menstrual period
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Although the typical Mediterranean diet constitutes a
large portion of vegetables and fruits rich in folate it is
uncertain whether this contributes to improved blood
folate levels in Italian fertile women. In the European
Prospective Investigation into Cancer and Nutrition co-
hort, women in South Europe, including Italy, appeared
to have higher plasma folate concentrations than those
in the northern, but not in the more central regions of
Europe [30]. Furthermore, in a recent Italian study ex-
cluding vitamin B supplement users [31], only a small
portion of women in childbearing age reached adequate
levels of serum folate and red blood cell folate according
to estimated thresholds for neural tube defect prevention
[31, 32]. In light of this, supplementation with folic acid
appears to be an important aspect also in countries with
Mediterranean diets.
Conclusions
In conclusion, like many women in other countries,
many Italian women start folic acid supplement use too
late with respect to neural tube defect prevention. Par-
ticularly, women who do not plan their pregnancy and
do not request a preconception health visit to the doctor
before the pregnancy have among the lowest prevalence
of preconception folic acid use. Increased folic acid pro-
motion during preconception health visits combined
with an even higher rate of both planned pregnancies
and preconception health visits might help improve sup-
plement use in Italian women. Alternatively, mandatory
food fortification with folic acid might be an option for
improving folate status, but more information on the
overall intake of folate from foods and supplements in
Italy is needed before considering such interventions.
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